HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by NASH, J. D. Articles by TALBERT, R. L. Search for Related Content PubMed PubMed Citation Articles by NASH, J. D. Articles by TALBERT, R. L. Agricola Articles by NASH, J. D. Articles by TALBERT, R. L.

Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans

College of Pharmacy, University of Texas at Austin, Departments of Pharmacology and Medicine, University of Texas Health Science Center at San Antonio and South Texas Veterans Health Care System San Antonio, TX, USA

Corresponding author: Dr D. S. Burgess (e-mail: burgessd{at}uthscsa.edu).

Received 15 Dec. 2000; revised version received 28 May 2001; accepted 27 June 2001.

Abstract

Synergy between fluvastatin, at clinically unachievable concentrations, and fluconazole against Candida albicans has been reported. The purpose of the present study was to evaluate the in-vitro activity of fluconazole alone and in combination with clinically achievable concentrations of pravastatin and fluvastatin against C. albicans. In-vitro susceptibility and synergy testing were performed against clinical isolates of C. albicans with fluconazole, pravastatin and fluvastatin. Both checkerboard method and time-kill studies were performed. MICs for fluconazole ranged from 0.5 (susceptible) to >256 mg/L (resistant) at 24 h. All isolates had MICs >2 mg/L for both statins. No synergy or antagonism was observed with fluconazole in combination with either agent against any isolate of C. albicans by the checkerboard assay or time-kill studies. Clinically achievable concentrations of pravastatin and fluvastatin did not affect the in-vitro activity of fluconazole against C. albicans.

This article has been cited by other articles:

				M. D. Johnson, C. MacDougall, L. Ostrosky-Zeichner, J. R. Perfect, and J. H. Rex Combination Antifungal Therapy Antimicrob. Agents Chemother., March 1, 2004; 48(3): 693 - 715. [Full Text] [PDF]